Finolizumab
Phase 2Monoclonal antibody
Finolizumab is one of 6 small molecule programs targeting Hypopharyngeal Carcinoma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Hypopharyngeal Carcinoma
#DrugCompanyPhaseTrials
1Taxol
TevaApproved
Adrucil
EElorac, Inc.
Approved
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Neoadjuvant Chemotherapy
JJapan Clinical Oncology Group
Phase 3
Neoadjuvant Chemotherapy and CCRT
FFudan University
Phase 3
Finolizumab
EEye & ENT Hospital of Fudan University
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Finolizumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details